ERBB2 and cancer: Tumors that were HER-2 positive, estrogen receptor and progestrone receptor negative, or triple-negative were statistifically significantly underrepresented in patients whose cancers were detected by mammography screening (P = 0.039, P < 0.0001, P < 0.0001, and P = 0.100, respectively; Table 3).